Orthofix director awarded 14,965 deferred stock units
Orthofix Medical Inc. director Alan Lee Bazaar received an equity award of 14,965 deferred stock units of common stock.
Rhea-AI Filing Summary
Orthofix Medical Inc. director Alan Lee Bazaar received an equity award of 14,965 deferred stock units of common stock. The units were granted at no cash cost and will vest in full on the first anniversary of the grant date, conditioned on continued board service.
After this grant, Bazaar holds 65,489 shares and units in total, including 42,929 previously reported deferred stock units and 700 shares acquired under Orthofix’s Stock Purchase Plan. Each deferred stock unit represents the right to receive one share of common stock, which will settle within 45 days after his service with Orthofix ends.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 14,965 | $0.00 | $0.00 |
Footnotes (2)
- F1. Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer.
- F2. Includes 42,929 previously reported deferred stock units and an aggregate of 700 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 10/31/2025 and 4/30/2026. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b).
Key Figures
Key Terms
deferred stock units financial
Stock Purchase Plan financial
Rule 16b-3(b)(5) regulatory
Section 16(b) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.